| Literature DB >> 35646746 |
Ali Dawood1,2,3,4, Samah Attia Algharib2,5,6, Gang Zhao1,2,4,7, Tingting Zhu1,2,4,7, Mingpu Qi1,2,4,7, Kong Delai1,2, Zhiyu Hao1,2,4,7, Marawan A Marawan1,8, Ihsanullah Shirani1,9, Aizhen Guo1,2,4,7.
Abstract
Mycoplasmas as economically important and pantropic pathogens can cause similar clinical diseases in different hosts by eluding host defense and establishing their niches despite their limited metabolic capacities. Besides, enormous undiscovered virulence has a fundamental role in the pathogenesis of pathogenic mycoplasmas. On the other hand, they are host-specific pathogens with some highly pathogenic members that can colonize a vast number of habitats. Reshuffling mycoplasmas genetic information and evolving rapidly is a way to avoid their host's immune system. However, currently, only a few control measures exist against some mycoplasmosis which are far from satisfaction. This review aimed to provide an updated insight into the state of mycoplasmas as pathogens by summarizing and analyzing the comprehensive progress, current challenge, and future perspectives of mycoplasmas. It covers clinical implications of mycoplasmas in humans and domestic and wild animals, virulence-related factors, the process of gene transfer and its crucial prospects, the current application and future perspectives of nanotechnology for diagnosing and curing mycoplasmosis, Mycoplasma vaccination, and protective immunity. Several questions remain unanswered and are recommended to pay close attention to. The findings would be helpful to develop new strategies for basic and applied research on mycoplasmas and facilitate the control of mycoplasmosis for humans and various species of animals.Entities:
Keywords: clinical implications; gene transfer; mycoplasmas; pantropic pathogens; vaccination; virulence factors
Mesh:
Substances:
Year: 2022 PMID: 35646746 PMCID: PMC9137434 DOI: 10.3389/fcimb.2022.855731
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073